Search results
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 8 hours agoMerck MRK will discontinue the Keytruda plus vibostolimab co-formulation arm of a phase III melanoma...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via AOL· 5 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 4 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 5 days ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 3 days agoKeytruda, approved for several types of cancer, alone accounts for around 45% of Merck’s total...
Americans Are Spending the Most Money on These 25 Prescription Drugs
Healthline· 2 days agoThe diabetes and weight loss medication semaglutide (Ozempic, Wegovy, and Rybelsus) topped the list....
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Zacks via Yahoo Finance· 1 day agoHere we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK),...
Top Stock Reports for Broadcom, Merck & Airbnb
Zacks· 3 days agoThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom ...
Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials
Investing.com· 2 days agoAIM ImmunoTech (NYSE: AIM ) Inc. (NYSE American: AIM) provided an optimistic update during its first...
...Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive......
Benzinga· 4 days agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that
